Peptides for Covid-19 prevention and treatment
Embodiments include therapeutic peptides for preventing or reducing the transmission of a coronavirus such as SARS-CoV2. Also included are methods of using therapeutic peptides for reducing or preventing transmission of a coronavirus such as SARS-CoV2. The therapeutic peptides can prevent a region of the surface glycoprotein “spike” on SARS-CoV2 from interacting with angiotensin converting enzyme-2 (ACE-2) of host cells.
1. A peptide having at least 70% sequence identity to SEQ ID NO: 1, wherein the peptide comprises a carboxy-terminal lysine residue and a biotin residue.
2. The peptide of claim 1 having at least 80% sequence identity to SEQ ID NO: 1.
3. The peptide of claim 1 having at least 90% sequence identity to SEQ ID NO: 1.
4. The peptide of claim 1 , further comprising one or more conservative amino acid substitutions.
5. The peptide of claim 1 , wherein a free carboxylic acid group of the lysine residue comprises an amide group.
6. The peptide of claim 1 , further comprising a thienoimidazole derivative.
7. The peptide of claim 1 , further comprising a FITC.
8. The peptide of claim 1 , further comprising a biotin residue, a thienoimidazole derivative, and FITC.
9. A peptide with amino acid sequence of SEQ ID NO: 1 that binds to ACE-2 receptor and prevents formation of a complex with SARS-CoV2.
10. The peptide of claim 9 , wherein the peptide is comprised of at least one of a lysine residue, a biotin residue, a thienoimidazole derivative, and a FITC.
11. The peptide of claim 9 , further comprising one or more conservative amino acid substitutions.
12. A method of preventing or treating a coronavirus virus infection in a patient that is susceptible to the virus infection, comprising steps of:
a) administering a peptide with amino acid sequence of SEQ ID NO: 1 to a respiratory system of the patient, and
b) preventing or attenuating formation of a complex between a viral surface protein and a receptor on a host cell.
13. The method of claim 12 , wherein the coronavirus is Covid-19.
14. The method of claim 12 , wherein the peptide comprises a carboxy-terminal lysine residue.
15. The method of claim 14 , wherein a free carboxylic acid group of the lysine residue comprises an amide group.
16. The method of claim 14 , wherein the peptide further comprises a biotin residue.
17. The method of claim 14 , wherein the peptide further comprises a thienoimidazole derivative.
18. The method of claim 14 , wherein the peptide further comprises a FITC.
19. The method of claim 12 , wherein the receptor on the host cell is angiotensin converting enzyme-2.
20. The method of claim 12 , wherein the viral surface protein is a S-glycoprotein.
21. The method of claim 12 , wherein the peptide is administered as a nasal spray or inhalant.
22. The method of claim 12 , wherein the peptide further comprises a pharmaceutically acceptable carrier.
23. A peptide with amino acid sequence of SEQ ID NO: 1 that binds to ACE-2 receptor and prevents an interaction between a viral surface protein of coronavirus and the ACE-2 receptor.
24. The peptide of claim 23 , wherein the viral surface protein is a S-glycoprotein.
25. The peptide of claim 23 , wherein the coronavirus is a Severe Acute Respiratory Syndrome 2 (SARS-CoV-2).
26. The peptide of claim 23 , wherein the peptide is comprised of at least one of a lysine residue, a biotin residue, a thienoimidazole derivative, and a FITC.
27. The peptide of claim 23 , wherein the peptide comprises a lysine residue and a free carboxylic acid group of the lysine residue comprises an amide group.